PharmaTelevision - The Diversification of Biotecnol

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: The Diversification of Biotecnol

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

Biotecnol is proof that a hybrid business model works. As its CEO, Pedro de Noronha Pissarra, explains in this interview, the revenue stream created by its contract research and manufacturing arm not only kept the company alive but also helped the company build up its platform technology. Recently, Biotecnol took the decision to separate the two businesses and is currently looking to raise capital for the development of its own pipeline. Here, Dr. de Noronha Pissarra describes the emergence of this unique Portuguese company and how he is focusing his efforts on raising the needed cash.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Origin of the business and its hybrid business model.

Fintan Walton:

Hello and welcome to PharmaVentures business review here in Mannheim, Germany. On this show I have Pedro Pissarra who is the CEO of a company called Biotecnol in Portugal. Welcome to the show.

Pedro de Noronha Pissarra:

Thank you very much. Good morning Fintan. Pleasure.

Fintan Walton:

Good morning to you. Pedro Biotecnol is a company that is focused on antibodies . It's quiet unique as it's a Portuguese company. It's built, it's presence up there over the last ten years. Tell us a little bit about the origins of the business and it's current business model?

Pedro de Noronha Pissarra:

It's a good proof that the hybrid model still works. we started as traditionally as a company doing services for third parties, contracted research, manufacturing development nothing very sexy about biotech in those days and we built upon developing our own pipeline every time. Nowadays we still keep both activities in terms of hybrid business model and but clearly we separating the two businesses in order to focus more on the antibody platforms. So we have this platform called the Tribody platform which it builds upon multifunctional antibody derivatives so that we can target two receptors or two targeting sites at the same time and build in a effective functions. But we are gonna keep still the contract manufacturing part because it creates quite an interesting revenue stream for the company.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Pedro de Noronha Pissarra

Chief Executive Officer

Pedro de Noronha Pissarra, CEO- Biotecnol Dr. Pedro de Noronha Pissarra obtained both his B.Sc. and Ph.D. in Biotechnology from Kings College London University of London. He carried out research at several institutions, including the Chemical Engineering Department of Massachusetts Institute of Technology M.I.T, Cambridge USA and at the Centre for Process Biotechnology (CPB) of the Technical University of Denmark, Lyngby, Denmark. In 1999 he finished a 12 months Masters Programme in the Science & Technology Management and Commercialization offered jointly by the IC2 Institute at the University of Texas, Austin, USA and Instituto Superior T"cnico, IST, Lisboa, Portugal. As well as founding and chairing the Portuguese Bio-industries Association (APBio) Pedro de Noronha Pissarra has been a member of the Advisory Group of the Biotechnology & Finance Forum, organized by the European Association of Security Dealers and Automated Quotations (EASD), and the European Commission's DG Research, a board member of Vida Rhein SA a German-Portuguese joint venture dedicated to Hepatitis B vaccines development, a member of the National Council of the National Entrepreneurs Association (ANJE) and is a member of the Emerging Enterprises sub-board of EuropaBio. Dr. de Noronha Pissarrais presently a member of the Superior Counsel for Science, Technology and Innovation of the Portuguese government, where he advises the Minister of Science and Technology and is also a visiting professor at the Catholic University of Oporto, where he teaches biopharmaceutical sciences.

Biotecnol

Biotecnol is a biopharmaceutical company focusing on the discovery, engineering and development of novel multifunctional antibody molecules, directed to key therapeutic targets. Based on it's Tribodytechnology, Biotecnol is developing a pipeline of products for application in major disease areas such as oncology . Founded in 1996 as a consultancy company, Biotecnol is now regarded as a pioneering Portuguese biotechnology company, and due to it's track record is considered to be the country's leading pharmaceutical biotech company. Today the company has expanded it's activities to the USA where it envisages carrying out it's product development activities.